• About us
• Contact

Advertisement

Organisation › Details

Karuna Therapeutics Inc. (Nasdaq: KRTX)

Karuna is a clinical-stage drug development company focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders including psychosis in schizophrenia, psychosis in Alzheimer’s disease, and pain. Karuna's lead product candidate, KarXT, (Karuna-Xanomeline-Trospium) is being evaluated in a Phase 2 clinical trial in patients with schizophrenia experiencing acute psychosis, with top-line results anticipated at the end of 2019. Karuna, which was founded by PureTech Health (LSE: PRTC), has a worldwide exclusive license for xanomeline and has a patent portfolio more broadly covering selective muscarinic targeting enabled by the KarXT approach. *

 

	Start	2019-03-18 renamed date ca
	Group	Bristol Myers Squibb (BMS) (Group)
	Predecessor	Karuna Pharmaceuticals Inc.
	Industry	CNS drug (neurological drug)
	Industry 2	KarXT (Karuna-xanomeline-trospium chloride)
	Region	Boston, MA
	Country	United States (USA)
	Street	33 Arch Street Suite 3110
	City	02110 Boston, MA
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Karuna Therapeutics, Inc.. (3/18/19). "Press Release: Karuna Announces $68 Million Series B Financing". Boston, MA.
		Record changed: 2023-12-23

Advertisement

More documents for Bristol Myers Squibb (BMS) (Group)

• [1] VantAI. (2/13/24). "Press Release: VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence". New York, NY....
• [2] GlycoEra AG. (1/5/24). "Press Release: GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer". Newton, MA & Wädenswil....
• [3] Bristol Myers Squibb Company. (12/26/23). "Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio". Princeton, NJ & San Diego, CA....
• [4] Bristol Myers Squibb Company. (12/22/23). "Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics". Princeton, N.J. & Boston, MA....
• [5] Armstrong, Annalee / Bayer, Max / Masson, Gabrielle [Fierce Biotech]. (12/22/23). "News: Fierce Biotech M&A Tracker 2023. BMS, AbbVie Drop Billions for Neuropsychiatry Biotechs"....
• [6] RayzeBio, Inc.. (9/19/23). "Press Release: RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares". San Diego, CA....
• [7] RayzeBio, Inc.. (9/14/23). "Press Release: RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering". San Diego, CA....
• [8] Immatics N.V.. (7/24/23). "Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb". Tübingen & Houston, TX....
• [9] Evotec SE. (7/11/23). "Press Release: Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership". Hamburg....
• [10] Evotec SE. (5/12/23). "Press Release: Evotec Publishes Annual Report 2022 and Quarterly Statement for Q1 2023". Hamburg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.